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Case reports
We present three cases of preimplantation genetic 
diagnosis (PGD) performed for hereditary cancer 
syndromes at the Centre of Assisted Reproduction 
and Embryology, The University of Hong Kong, 
Queen Mary Hospital in Hong Kong.
Case 1
A 33-year-old woman was referred for consideration 
of PGD because she was a BRCA2 gene mutation 
carrier. She had cancer of the right breast at 
the age of 24 years and underwent modified 
radical mastectomy with axillary dissection and 
immediate latissimus dorsi flap reconstruction. 
Adjuvant chemoradiotherapy was given and she 
was prescribed tamoxifen for 5 years after the 
operation. Her paternal grandmother had breast 
cancer diagnosed at the age of 60 years. Genetic 
screening was performed and confirmed the patient 
to be a BRCA2 mutation carrier. Her elder brother 
and her father underwent the spot test and were 
found to carry a BRCA2 mutation but her younger 
sister was not affected. Laparoscopic ovarian 
cystectomy was performed for a hyperechoic cyst 
noted over the right ovary, which was confirmed to 
be an endometriotic cyst. After a multidisciplinary 
meeting of clinical geneticists, breast surgeons, 
oncologists, gynaecologists, psychologists, nurses, 
and academics in the ethics department, followed by 
psychological assessment and also counselling, she 
was offered in-vitro fertilisation (IVF) and PGD. Her 
IVF and PGD cycle was performed in 2011, using 
an antagonist protocol with letrozole co-treatment. 
Fifteen oocytes were retrieved and 12 were fertilised 
following intracytoplasmic sperm injection (ICSI). 
Blastomere biopsy was performed on eight good-
quality cleaving embryos and five were confirmed 
to be free of the BRCA2 mutation. Two unaffected 
blastocysts were transferred, resulting in a singleton 
pregnancy and one unaffected blastocyst was 
cryopreserved. She delivered a baby boy at term by 
caesarean section. Postnatal cord blood confirmed 
Hong Kong Med J 2016;22:289–91
DOI: 10.12809/hkmj144499
that the baby boy did not carry the BRCA2 mutation.
Case 2
A 33-year-old woman was referred for PGD because 
she was a carrier of FAP truncating germline mu-
tation APC c.532-8G>A (NG_008481:g93262G>A) 
with a strong family history of colonic cancer. She 
underwent colonoscopy surveillance and more than 
100 small colonic polyps were found. She was advised 
to have a prophylactic colectomy but was firm in her 
request to get pregnant with PGD treatment before 
the definitive treatment while fully understanding 
the risks of malignancy because of the delay in 
definitive treatment. She underwent an IVF cycle in 
2012. Of 19 oocytes retrieved, 16 underwent ICSI. 
Fifteen were fertilised and 15 embryos were available 
for blastomere biopsy on day 3. Five embryos were 
found without the FAP mutation and four good-
quality blastocysts were cryopreserved due to the risk 
of ovarian hyperstimulation syndrome. She failed to 
conceive in two frozen embryo transfer (FET) cycles 
with one blastocyst replaced in each cycle. She 
subsequently underwent the last FET cycle with two 
blastocysts transferred, and a consequent singleton 
pregnancy. The pregnancy is 26 weeks’ gestation at 
the time of writing. The couple refused an invasive 
prenatal test and requested postnatal cord blood 
confirmation. 
Case 3
A 37-year-old patient was referred from a clinical 
geneticist for PGD as her husband was diagnosed to 
have neurofibromatosis type I and was a carrier of 
c.4495 C to T (p.Gln1499X) mutation in NF1 gene. 
The mutation is a nonsense mutation that changes 
the codon to a STOP codon. This mutation has 
not been reported to be associated with NF1, but 
such mutation is expected to result in a truncated 
protein product and is therefore very likely to be 
pathogenic. The couple were counselled accordingly 
and were very keen for PGD treatment. The woman 
underwent the first IVF cycle but only four oocytes 
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were retrieved. Two mature oocytes were injected 
but only one was fertilised. The couple requested 
cryopreservation of the only embryo on day 2. She 
underwent a second IVF cycle with five oocytes 
retrieved: four mature oocytes underwent ICSI 
and three were fertilised. The cryopreserved day-2 
embryo from the first cycle was thawed and cultured 
for 24 hours. A total of four embryos were available 
for embryo biopsy on day 3 and three were found 
to lack the NF1 mutation. Two blastocysts were 
transferred with a resulting singleton pregnancy. One 
surplus blastocyst was cryopreserved. After detailed 
counselling, the couple requested amniocentesis to 
confirm the PGD diagnosis and amniocentesis will 
be arranged at 16 to 18 weeks’ gestation (at the time 
of writing the pregnancy is 14 weeks’ gestation).
Pre-preimplantation genetic 
diagnosis workup and 
preimplantation genetic  
diagnosis cycle
Case 1
The exact genomic deletion breakpoints on the 
BRCA2 gene were unknown when the patient first 
presented to us (the breakpoint was subsequently 
studied—c.7436_7805del [GeneBank U43746])1 and 
the DNA of the patient’s parents was unavailable. 
Therefore we tried to establish the haplotype around 
the BRCA2 gene with the sibling DNA of the non-
carrier sister and carrier brother. Nonetheless, the 
patient shared no common haplotype with her non-
carrier sister and had exactly the same haplotype as 
her carrier brother around the BRCA2 gene. Finally, 
the high-risk haplotype was delineated by haplotype 
analysis of single sperms from her carrier brother. A 
PGD protocol was established that involved whole-
genome amplification,2 linkage analysis with intragenic 
single-nucleotide polymorphism markers (rs1801406 
and rs1799955) and flanking micro-satellite markers 
D13S289, D13S1698, D13S1701 and D13S171, located 
within 2 Mb region flanking BRCA2 gene. 
Case 2 
Case 2 was a carrier of APC c.532-8G>A 
(NG_008481:g93262G>A). The mutation was directly 
determined by minisequencing with SNaPshot 
Multiplex Kit (Applied Biosystems, Foster City, US). 
Linkage analysis was performed by the haplotyping 
method3 on a panel of 8 to 10 informative/partially 
informative microsatellite markers located within 
a 2 Mb region flanking the APC gene. During 
the pre-PGD workup, neither sibling DNA nor 
offspring DNA was available to establish the high-
risk haplotype, therefore high-risk haplotype was 
deduced from the genotype of embryos during 
PGD treatment cycles, by correlating the result of 
minisequencing and linkage analysis. 
Case 3
The husband of case 3 was a carrier of mutation 
NF1c.4495C>T (NM_000267). Mutation was 
directly determined by minisequencing and linkage 
analysis was performed on six informative/partially 
informative markers located within 2 Mb region 
flanking NF1 gene. The high-risk haplotype was 
established by single-sperm haplotype analysis in 
the husband.
 All PGD protocols were extensively validated 
against 40 single lymphocytes (20 maternal and 20 
paternal) of the corresponding couples. During the 
PGD treatment cycle, all biopsied embryos resulted 
in a definitive diagnosis. 
Discussion
The British Society of Gastroenterology recommends 
that all families with familial adenomatous polyposis 
(FAP) and Lynch syndrome should be screened 
in the context of a registry. A systematic review 
revealed that registration and screening resulted in a 
significant reduction in colorectal cancer incidence 
and mortality.4 With earlier detection of these 
cancer syndromes and a better surveillance system, 
patient survival is improved.5 As prenatal diagnosis 
is not a widely acceptable reproductive option, PGD 
to reduce the chance of having offspring with the 
same genetic predisposition to cancer is probably an 
attractive option after detailed counselling regarding 
the procedures and ethical concerns. It also avoids 
the need for termination. One recent study from 
the Netherlands showed that PGD is an acceptable 
choice for couples with hereditary breast and ovarian 
cancer (HBOC).6 
 In the first decade after the first published paper 
on PGD, the technique was used as an alternative 
to prenatal diagnosis for severe lethal inherited 
diseases.7 Indications for PGD have since been 
extended to adult-onset diseases such as Huntington 
chorea and spinocerebellar ataxia as well as diseases 
with incomplete penetrance such as hereditary cancer 
syndromes. It has been challenged ethically and the 
use of PGD in these indications was controversial,8 
although both ESHRE (European Society of Human 
Reproduction and Embryology9) and HFEA (Human 
Fertilisation & Embryology Authority; www.hfea.
gov.uk) accepted these adult-onset and multifactorial 
diseases as indications for PGD.
 Ovarian stimulation used for IVF treatment 
may trigger a high oestradiol concentration that 
may theoretically increase the risk of recurrence of 
hormone receptor–positive breast cancer. The use 
of letrozole to suppress the oestradiol concentration 
during IVF has been successful; some large case 
series have reported a comparable breast cancer 
recurrence rate in those who did and did not undergo 
IVF.10,11 A case-control study also revealed that even 
without letrozole, IVF treatment does not appear to 
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increase the chance of breast cancer in BRCA gene 
mutation carriers.12 
 The use of prenatal invasive tests, such as 
chorionic villus sampling and amniocentesis, to 
confirm PGD results is controversial in adult-onset 
diseases with incomplete penetrance with the need 
for termination of pregnancy if the fetus is affected.13 
In our case series, only one couple out of three 
accepted the use of invasive prenatal tests and the 
possibility of termination. A recent study revealed 
that a proportion of couples with HBOC refused 
prenatal testing even following natural conception.6 
In view of the growing number of requests for 
postnatal cord blood confirmation for these adult-
onset multifactorial diseases, its use in FAP families 
was discussed in our PGD ethics committee. This 
committee comprised reproductive medicine 
subspecialists, a clinical geneticist, maternal fetal 
medicine subspecialists, and laboratory in-charge. 
The pros and cons of postnatal testing were discussed. 
Since the risk of extra-colonic malignancies, such 
as hepatoblastoma, in FAP families is about 500 to 
750 times that of the general population and the 
diagnosis is usually made before the age of 3 years,14 
early diagnosis with postnatal confirmation of 
possible incorrect PGD diagnosis in order to have 
appropriate surveillance for these lethal malignancies 
would be considered worthwhile. A large case 
series also showed the importance of surveillance 
in paediatric FAP carriers of whom a considerable 
proportion with malignancies required treatment.15 
The choice of using invasive prenatal procedures 
or postnatal cord blood testing to confirm a PGD 
diagnosis depends on discussion between the couple 
and the multidisciplinary team about the variable 
presentation of different syndromes. 
 Although PGD can be a practical and sound 
reproductive option for couples with hereditary 
cancer syndromes, awareness and knowledge of this 
technique is lacking even in prosperous developed 
countries such as the United States where PGD 
treatment is readily available.16,17 More information 
about PGD should be available to the general 
population, so that those who need this technique 
have access to this option and appropriate counselling. 
Conclusion
The use of PGD is an alternative reproductive option 
for hereditary cancer syndromes. With good case 
selection, a multidisciplinary approach and support 
for the patient and family, this can be an acceptable 
option that takes account of the ethical concerns. 
More information about this technique should be 
provided to the general population and families with 
hereditary cancer syndromes.
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